Logo image of SNGX

SOLIGENIX INC (SNGX) Stock Fundamental Analysis

NASDAQ:SNGX - Nasdaq - US8342236044 - Common Stock - Currency: USD

1.93  +0.02 (+1.05%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SNGX. SNGX was compared to 560 industry peers in the Biotechnology industry. SNGX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SNGX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SNGX had negative earnings in the past year.
SNGX had a negative operating cash flow in the past year.
SNGX had negative earnings in each of the past 5 years.
In the past 5 years SNGX always reported negative operating cash flow.
SNGX Yearly Net Income VS EBIT VS OCF VS FCFSNGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

SNGX has a Return On Assets of -92.19%. This is in the lower half of the industry: SNGX underperforms 73.39% of its industry peers.
With a Return On Equity value of -200.74%, SNGX is not doing good in the industry: 68.04% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -92.19%
ROE -200.74%
ROIC N/A
ROA(3y)-83.84%
ROA(5y)-77.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SNGX Yearly ROA, ROE, ROICSNGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K 30K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SNGX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNGX Yearly Profit, Operating, Gross MarginsSNGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

5

2. Health

2.1 Basic Checks

SNGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
SNGX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SNGX has been increased compared to 5 years ago.
SNGX has a better debt/assets ratio than last year.
SNGX Yearly Shares OutstandingSNGX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
SNGX Yearly Total Debt VS Total AssetsSNGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

SNGX has an Altman-Z score of -38.68. This is a bad value and indicates that SNGX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SNGX (-38.68) is worse than 92.14% of its industry peers.
SNGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -38.68
ROIC/WACCN/A
WACC10.09%
SNGX Yearly LT Debt VS Equity VS FCFSNGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

SNGX has a Current Ratio of 1.82. This is a normal value and indicates that SNGX is financially healthy and should not expect problems in meeting its short term obligations.
SNGX has a worse Current ratio (1.82) than 78.39% of its industry peers.
SNGX has a Quick Ratio of 1.82. This is a normal value and indicates that SNGX is financially healthy and should not expect problems in meeting its short term obligations.
SNGX has a Quick ratio of 1.82. This is in the lower half of the industry: SNGX underperforms 77.14% of its industry peers.
Industry RankSector Rank
Current Ratio 1.82
Quick Ratio 1.82
SNGX Yearly Current Assets VS Current LiabilitesSNGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

4

3. Growth

3.1 Past

SNGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.06%, which is quite impressive.
Looking at the last year, SNGX shows a very negative growth in Revenue. The Revenue has decreased by -85.78% in the last year.
SNGX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -51.88% yearly.
EPS 1Y (TTM)66.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.19%
Revenue 1Y (TTM)-85.78%
Revenue growth 3Y-47.39%
Revenue growth 5Y-51.88%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, SNGX will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.53% on average per year.
SNGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 34.66% yearly.
EPS Next Y42.41%
EPS Next 2Y28.95%
EPS Next 3Y19.53%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y56.27%
Revenue Next 3Y34.66%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SNGX Yearly Revenue VS EstimatesSNGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2026 2027 2M 4M 6M 8M 10M
SNGX Yearly EPS VS EstimatesSNGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -500 -1K -1.5K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNGX. In the last year negative earnings were reported.
Also next year SNGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNGX Price Earnings VS Forward Price EarningsSNGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNGX Per share dataSNGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3 -4

4.3 Compensation for Growth

SNGX's earnings are expected to grow with 19.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.95%
EPS Next 3Y19.53%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SNGX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOLIGENIX INC

NASDAQ:SNGX (5/28/2025, 8:01:02 PM)

1.93

+0.02 (+1.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)08-07 2025-08-07
Inst Owners1.35%
Inst Owner Change421.79%
Ins Owners0.02%
Ins Owner Change0%
Market Cap6.29M
Analysts82.86
Price Target22.95 (1089.12%)
Short Float %2.34%
Short Ratio0.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.1%
Min EPS beat(2)-17.65%
Max EPS beat(2)29.84%
EPS beat(4)3
Avg EPS beat(4)11.74%
Min EPS beat(4)-17.65%
Max EPS beat(4)29.84%
EPS beat(8)6
Avg EPS beat(8)25.62%
EPS beat(12)8
Avg EPS beat(12)-7.91%
EPS beat(16)11
Avg EPS beat(16)-0.27%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-85.37%
Min Revenue beat(4)-100%
Max Revenue beat(4)-42.63%
Revenue beat(8)2
Avg Revenue beat(8)-43.67%
Revenue beat(12)5
Avg Revenue beat(12)-10.77%
Revenue beat(16)6
Avg Revenue beat(16)-16.78%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)61.93%
EPS NY rev (1m)-11.65%
EPS NY rev (3m)-17.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 52.74
P/FCF N/A
P/OCF N/A
P/B 1.53
P/tB 1.53
EV/EBITDA N/A
EPS(TTM)-4.29
EYN/A
EPS(NY)-2.06
Fwd EYN/A
FCF(TTM)-2.58
FCFYN/A
OCF(TTM)-2.58
OCFYN/A
SpS0.04
BVpS1.26
TBVpS1.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -92.19%
ROE -200.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-83.84%
ROA(5y)-77.43%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.82
Quick Ratio 1.82
Altman-Z -38.68
F-Score2
WACC10.09%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.19%
EPS Next Y42.41%
EPS Next 2Y28.95%
EPS Next 3Y19.53%
EPS Next 5YN/A
Revenue 1Y (TTM)-85.78%
Revenue growth 3Y-47.39%
Revenue growth 5Y-51.88%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y56.27%
Revenue Next 3Y34.66%
Revenue Next 5YN/A
EBIT growth 1Y-22.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.33%
OCF growth 3YN/A
OCF growth 5YN/A